Literature DB >> 28848988

Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

.   

Abstract

The first clinical guidelines for male lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) were published in 2005. An update is urgently needed in view of BPH being recognised as one of ten chronic illnesses by the Ministry of Health, Singapore. This review summarises the definition of BPH and the epidemiology of male LUTS/BPH in Singapore. BPH can be phenotyped with noninvasive transabdominal ultrasonography, according to intravesical prostatic protrusion and prostate volume, and classified according to severity (staging) for individualised treatment. At the initial evaluation, the majority of patients (59%) can be managed with fluid adjustment, exercise and diet; 32% with medications, using alpha blockers and/or 5-alpha reductase inhibitors for prostates weighing more than 30 g; and 9% with surgical intervention for more advanced disease. The 2015 guidelines comprise updated evidence that will help family medicine practitioners and specialists manage this common ailment more cost-effectively. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  benign prostatic hyperplasia; clinical guidelines; intravesical prostatic protrusion; male lower urinary tract symptoms; staging of clinical BPH

Mesh:

Substances:

Year:  2017        PMID: 28848988      PMCID: PMC5563527          DOI: 10.11622/smedj.2017082

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  43 in total

1.  Effects of bladder volume on transabdominal ultrasound measurements of intravesical prostatic protrusion and volume.

Authors:  John Shyi Peng Yuen; James Tan Khiaw Ngiap; Christopher Wai Sam Cheng; Keong Tatt Foo
Journal:  Int J Urol       Date:  2002-04       Impact factor: 3.369

2.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

3.  Plasmakinetic enucleation of the prostate vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: comparison of outcomes according to prostate size in 310 patients.

Authors:  Yu-Hui Luo; Ji-Hong Shen; Run-Yun Guan; Hao Li; Jia Wang
Journal:  Urology       Date:  2014-08-19       Impact factor: 2.649

4.  The prevalence of lower urinary tract symptoms and treatment-seeking behaviour in males over 40 years in Singapore: a community-based study.

Authors:  C Chong; L Fong; R Lai; Y T Koh; W K O Lau; M Hartman; S E Chia
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-02-21       Impact factor: 5.554

Review 5.  Serenoa repens for benign prostatic hyperplasia.

Authors:  James Tacklind; Roderick Macdonald; Indy Rutks; Judith U Stanke; Timothy J Wilt
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 6.  Pygeum africanum for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  Staging of benign prostate hyperplasia is helpful in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia.

Authors:  Delin Wang; Keong Tatt Foo
Journal:  Ann Acad Med Singapore       Date:  2010-10       Impact factor: 2.473

8.  Current assessment and proposed staging of patients with benign prostatic hyperplasia.

Authors:  K T Foo
Journal:  Ann Acad Med Singapore       Date:  1995-07       Impact factor: 2.473

9.  Alpha blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2007

10.  Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial.

Authors:  Brian Hill; William Belville; Reginald Bruskewitz; Muta Issa; Ramon Perez-Marrero; Claus Roehrborn; Martha Terris; Michael Naslund
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

View more
  1 in total

1.  Kangquan Recipe Regulates the Expression of BAMBI Protein via the TGF-β/Smad Signaling Pathway to Inhibit Benign Prostatic Hyperplasia in Rats.

Authors:  Wenfan Chen; Xiaoqing Huang; Axiang Peng; Tingting Chen; Renzhi Yang; Yuanpeng Huang; Zongbao Yang; Shengyan Xi
Journal:  Evid Based Complement Alternat Med       Date:  2019-05-02       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.